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Abstract
Background: To date, recombinant tissue plasminogen activator (rtPA) is the only approved drug for ischemic
stroke. It is intravenously administered functioning as a thrombolytic agent and is used to obtain reperfusion of the
affected area of the brain. Excitotoxicity, inflammation and apoptosis are all involved in delayed neuronal death
following stroke and offer multiple opportunities to intervene with neuroprotective agents. Gelsolin (GSN) is an
actin- and calcium-binding protein mediating the disassembly of actin filaments and activity of calcium channels. It
also functions as a regulator of apoptosis and inflammatory responses. This study tests the hypothesis that
increasing the concentration of the form of GSN known as plasma GSN (pGSN) near an infarct will provide
neuroprotection following ischemic stroke.
Methods: We induced middle cerebral artery occlusion (MCAO) in male rats via intracranial injection of endothelin-
1 (ET-1), a potent vasoconstrictor, and then treated with local delivery of pGSN. Whole brain laser Doppler
perfusion imaging was performed through the skull to assess MCAO effectiveness. Cylinder and vibrissae tests
evaluated sensorimotor function before and 72 h after MCAO. Infarct volumes were examined 72 h after MCAO via
2, 3, 5-triphenyltetrazolium chloride (TTC) assay.
Results: Estimates of relative cerebral perfusion were significantly decreased in all groups receiving MCAO with no
differences detected between treatments. Despite equivalent initial strokes, the infarct volume of the pGSN
treatment group was significantly reduced compared with the untreated MCAO rats at 72 h. ET-1 induced
significant deficits in both cylinder and vibrissae tests while pGSN significantly limited these deficits.
Conclusion: Gelsolin could be a promising drug for protection against neurodegeneration following ischemic
stroke.
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Introduction
Stroke or brain attack occurs when the blood supply to
the brain is interrupted, usually because a blood vessel
is blocked by a clot or loses structural integrity permit-
ting hemorrhage. The disease is not subject to a particu-
lar race or ethnic group [1]. In 2009, 795, 000 strokes
occurred in the United States, i.e. a stroke occurs once
every 40 seconds and a death occurs every 4 minutes
[2]. According to the Centers for Disease Control and
Prevention (CDC), the total cost of stroke was $68.9
billion and the number is expected to rise. Of all
strokes, 87% are ischemic [2]. Currently, recombinant
tissue plasminogen activator (rtPA) is the only FDA-
approved therapeutic agent for ischemic stroke. rtPA is
effective only if intravenously administered within 3 to
4.5 h of stroke onset, and can have adverse neurotoxic
effects even with proper use [3]. The drug can only be
used within a narrow time window after a stroke begins
a n do n l ya b o u tt w op e r c e n to fs t r o k ep a t i e n t sa r ea b l e
to access rtPA therapy. Therefore, development of new
agents for stroke is essential.
The mechanisms involved in stroke injury and repair
are extremely complex, involving excitotoxicity and
necrotic cell death occurringw i t h i nm i n u t e so fs t r o k e
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that genetically programmed cell death during post-
ischemic tissue inflammation (that can last days to
weeks) has a detrimental effect [5,6]. Therefore, thera-
peutic strategies targeting that delay or dampening
inflammatory responses could inhibit the progression of
t h et i s s u ed a m a g ea n di m p r o v et h eo v e r a l lo u t c o m eo f
stroke.
Gelsolin (GSN) is a ubiquitous [7,8] actin filament-
severing, capping and actin nucleation protein of eukar-
yotes. Originally described as an actin-binding protein,
GSN exists in both intracellular (cytoplasmic protein,
cGSN) and extracellular (a secreted protein or plasma
gelsolin, pGSN) forms. pGSN, also known as brevin and
actin-depolymerizing factor, consists of a single 755-
amino acid polypeptide chain (84 kDa) including a 25-
amino acid N-terminal extens i o n[ 9 ]t h a td i s t i n g u i s h e s
it from cGSN (82 kDa). Most cells secrete pGSN, how-
ever smooth, skeletal and cardiac muscle cells produce
larger amounts of pGSN [7]. The plasma concentration
of pGSN is 200-300 mg/L [10-12] and isolated human
and rabbit pGSN have a plasma half-life of 2.3 days
[13]. Because pGSN derives from muscle tissue, it must
pass through interstitial fluid of the extracellular matrix
to localize in the blood. pGSN also exists in human cer-
ebrospinal fluid (CSF) [14]. Although certain functions
for the intracellular isoforms have been described, the
function(s) of the plasma isoforms remain unclear. The
high affinity of pGSN for filamentous actin (F-actin) (Ka
>1 0
9/mol/L) [15] suggests that its physiological function
is likely related to its actin-binding properties. pGSN
may scavenge actin leaked from injured tissue and limit
subsequent damage instigated by extracellular filamen-
tous actin [16]. Studies have shown that large amounts
of F-actin could potentially increase the blood viscosity
and perturb blood flow through the microvasculature
[17].
It is also well established that pGSN levels decrease in
blood in acute inflammation conditions that involve tis-
sue damage [18-21]. Consistent with the idea that pGSN
is not only a biomarker for inflammation but also an
important protective factor, repletion of pGSN in a
mouse model of endotoxemic sepsis led to solubilization
of circulating actin aggregates and significantly reduced
mortality in mice [22]. GSN knockout mice neurons are
vulnerable to glucose/oxygen deprivation, and pharma-
cological brain actin depolymerization restored resis-
tance to ischemic stroke ink n o c k o u tm i c e[ 2 3 ] .T h e
knockout mice results could not determine which endo-
genous form of gelsolin is responsible, or whether gelso-
lin in or near the infarct mediates neuroprotective
effects. Gelsolin-overexpressing transgenic mice demon-
strate neuroprotection against experimental stroke [23],
but it is not known whether these effects are mediated
by pGSN or cGSN, or whether it is GSN near the
infarct that mediates the protection.
To test the hypothesis that proximal administration of
pGSN can antagonize stroke pathology, we induced
transient middle cerebral artery occlusion (tMCAO) in
male rats via intracranial injection of ET-1, a potent
vasoconstrictor, and post-treated with discrete brain
injection of pGSN. Cylinder and vibrissae tests were
used to examine sensorimotor function before and 72 h
after MCAO to assess functional deficits. Whole brain
laser Doppler perfusion imaging was performed through
the skull to verify MCAO effectiveness. Infarct volumes
were examined 72 h after MCAO using 2, 3, 5-triphe-
nyltetrazolium chloride (TTC) assay.
Materials and methods
Materials
Endothelin-1 (1-39) rat (ET-1), purchased from Ameri-
c a nP e p t i d eC o m p a n y ,I n c .( C A ,U . S . A . ) ,w a sd i s s o l v e d
in sterile phosphate buffered saline (PBS) to make a
stock concentration of 80 μM. The stock solution was
stored at -20°C. ET-1 was thawed, centrifuged and
placed on ice until ready to inject. Human plasma gelso-
lin (pGSN) was a generous gift from Critical Biologics
Corporation (MA, U.S.A.) Artificial cerebrospinal fluid
(aCSF) was obtained from Fisher Scientific, Inc. (PA, U.
S.A.)
Animal model
Experiments were conducted on 19 male Sprague-Daw-
ley rats weighing from 210-270 g. Animals were ran-
domly divided into five groups: two groups of three for
laser Doppler measurement, two groups of five for
experimental ischemic stroke by ET-1 plus pGSN or
control injections, with evaluation of behavior and brain
damage, a group of three for artificial cerebrospinal fluid
(aCSF) injection. Two animals in the group of five
injected with ET-1 alone were eliminated from the
study: one died on day 2 and one did not show any
movement in behavioral studies. One animal was elimi-
nated from the ET-1 plus pGSN group since we could
not define the infarction area. The exclusion rate was 3/
13 for the treatment study and 0/6 for the laser Doppler
study. All procedures were implemented according to a
protocol approved by the University of Florida Institu-
tional Animal Care and Use Committee (IACUC).
A model of reversible focal ischemia using ET-1 was
used as previously described [24,25]. When ET-1 is
injected proximal to the middle cerebral artery (MCA),
it acts on vascular smooth muscle cell receptors ETA
and ETB [26], causing arterial constriction and reduced
blood flow to areas in the brain supplied by the ipsilat-
eral MCA (anterolateral neocortex, cortical areas, and
caudate nucleus). Anesthesia was initiated with
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O2). Body temperature was maintained between 36.5-
37.5°C throughout surgery using a water-jacketed heat-
ing blanket. The animals were placed in a stereotaxic
frame (Braintree Scientific, Inc., MA, U.S.A.) and
secured in the flat skull position. A midline incision was
made spanning the bregma and lambda landmarks, and
a small hole (3 mm i.d) was drilled in the cranium adja-
cent to the left MCA (coordinates: 0.2 mm anterior, 5.2
mm lateral, and 1 mm dorsal to the bottom of the
skull). A 27-gauge needle was used to inject 3 μL of ET-
1 (240 pmol) at 1 μL/min. After ET-1 injection, the nee-
dle was left in place for an additional 3 min before being
slowly withdrawn. The system was flushed by DI water
and pGSN was loaded in the needle. Approximately, 5-
10 min after ET-1 injection, 3 μLo fp G S N( 3μgo r
35.71 pmol) was injected, after which the needle was
again left in place for 3 min, then slowly removed. The
incision was closed and animals were kept warm at 37°C
until totally recovered from anesthesia.
Cerebral Perfusion Measurement
In each animal, skin on the scalp was removed and two
holes (3 mm i.d) were made above in each hemisphere.
ET-1 or ET-1 plus pGSN were injected in the left side
of the brain and the other side was used as an internal
control. Relative blood flux/perfusion measurements
were made using Laser Doppler (MOORLDI, Moor
Instrument Ltd, UK) at four different time points: pre-
injection, 10-20 min, 30-35 min, and 55-65 min from
the ET-1 injection time. The measurements were based
on the moving blood in the microvasculature that
causes a Doppler frequency shift of the scattered laser
light, which is photodetected and then processed to
build a color coded map of relative blood flow. A digital
camera records a color clinical photograph at the same
time, corresponding closely with the blood flow image
in size and aspect. The pseudocoloring is relative flux
(number of red blood cells multiplied by speed) where
“warm” colors indicate relative high flux and “cool” col-
ors represent relative low flux. The 16- bit color scans
were made with arbitrarily assigned unit from 0 (lower
limit) to 1, 000 or more (upper limit). The scan speed
was 10 ms/pixel and the total scan (scan area was about
1.8 cm × 2.3 cm) duration per animal was approxi-
mately 10 min. Actual blood flow is impossible to mea-
sure with Laser-Doppler flowmetry (LDF), but is highly
correlated to flux except at supranormal pressures [27].
Indeed, percentage reductions of cerebral perfusion are
actually relative percentage reductions of flow and were
calculated using the following formula:

Pi/Pc

× 100% (1)
where Pi is flow values at ipsilateral side (injected side)
and Pc is flow values at contralateral side (unaffected
side); both are measured in perfusion unit (PU)
Behavioral tests
Behavioral tests used include the limb-use asymmetry
(cylinder) and vibrissae-stimulated forelimb placing
(vibrissae) for somatosensory asymmetry. Animals were
tested before and 72 h post-surgery. The cylinder test
examines the level of preference for using the non-
impaired forelimb for weight shifting movements during
spontaneous vertical exploration. Non-infarcted animals
typically use both limbs equally for upright support, but
after damage to the motor system, animals show an
asymmetric reliance on the less-affected (ipsilateral)
limb [28]. Rats were placed in a specially designed trans-
parent cylinder (20 cm i.d, 40 cm height) for 3 min. The
cylinder was high enough that the animal could not
reach the top edge or escape, but encourages vertical
exploration of the glass walls with the forepaws as well
as landing (return to floor) activity. Forepaw use during
exploration of the rats was scored by analyzing slow-
motion playback of digital video recorded from a camera
installed over the cylinder, by an experimenter blind to
the treatment condition. The fraction of events in which
the animal used the ipsilateral (affected), contralateral
(un/less affected), or both forelimbs was calculated as a
dependent measure of asymmetry.
Vibrissae-stimulated forepaw and extinction placing
tests evaluate sensorimotor/proprioceptive deficits. To
determine whether an animal has asymmetrical sensori-
motor perception, the animal is held by the torso with
its forelimbs hanging freely, and then slowly moved lat-
erally toward the edge of the table or countertop until
the vibrissae of one side makes contact with the edge.
Intact rats quickly place the ipsilateral forepaw on the
edge or the surface of the table when the ipsilateral
vibrissae brush the table edge. In contrast, rats with
damage to the motor system often do not respond to
vibrissae stimulation on the affected side (contralateral
side). Using Windows Movie Maker 2007 (Microsoft), a
treatment-blinded viewer scored digital video records
for each side, using the frame rate and the number of
frames between vibrissae stimulation and forepaw con-
tact to determine placing response delay intervals.
Histology
Animals were sacrificed at 72 h for TTC staining. The
brains were quickly isolated, placed in cold PBS (0-4°C)
for 30 min and then sectioned into 2-mm thick coronal
slices using a brain slice matrix (Leica Microsystems, IL,
U.S.A.) The tissue sections were held in cold PBS for 3
min before they were incubated in TTC solution (0.05%
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washed three times with PBS (one minute each) and
fixed in 0.1 M phosphate buffered formaldehyde (PBF).
The sections then were placed on a flatbed scanner
(EPSON 1680) to obtain images.
Infarction Area Analysis
Calibrated digital images of tissue sections were made at
600-dpi scanner resolution with 48-bit color and saved
as TIFF files. The infarction areas were quantified by
visual thresholding of TTC-labeled (normal) and unla-
beled (infarct) tissue, and measurement of each area,
using Image J version 5.0 (NIH). Infarct volume was
estimated as the product of area on each section and
the number of 2 mm sections exhibiting infarct. The
ratio of infarct to normal volume was used as dependent
measures for evaluating pGSN effects.
Statistical analysis
All data are expressed as arithmetic means ± s.e.m.
Two-way ANOVA (time and treatment) was followed
by Bonferroni post hoc test to compare behavioral
dependent variables between groups. Comparisons of
i n f a r c ta r e aw e r em a d eb yt w o - t a i l e dS t u d e n t ’st - t e s t ;
and p-values less than 0.05 were considered to be
significant.
Results
Treatment of pGSN did not interrupt ET-1 induced artery
contraction
In order to test the effect of pGSN and ET-1 on
MCAO, cohorts (n = 3) of rats were injected with ET-
1 to induce transient middle cerebral artery occlusion
(MCAO). Approximately 5-10 min after ET-1 injec-
tion, pGSN or saline was injected at the same location.
The time points of scanning were based on ET-1 injec-
tion time. The relative perfusion unit (PU) or blood
flow values of animals before injection were in the
range of 800-1, 600 PU and the difference between
two hemispheres of the brain was not statistically sig-
nificant. After 20 min following ET-1 injection, the
flux values on the injection side dropped to the range
of 300-600 PU. The calculations were made using for-
mula 1 described in the methods. Relative flow values
showed a rapid decrease to ~ 50% of baseline in all
animals and flow remained maximally decreased for
20-30 min after ET-1 injection (Figure 1). ET-1 injec-
tion resulted in a drop in perfusion immediately after
injection regardless of pGSN injection at the same
location. Reperfusion was observed in both groups
after ~ 60 min. These results indicate that pGSN injec-
tion did not interrupt the induction of artery contrac-
tion by ET-1.
Treatment of pGSN significantly reduced ET-1 induced
behavioral deficits
To test the protective effect of pGSN, behavioral studies
were conducted. Initially, five rats were randomly
assigned into ET-1 injection alone or ET-1 plus pGSN
group. In the ET-1 only group, one rat died and one rat
was paralyzed after ET-1 injection and was euthanized
immediately. In ET-1 plus pGSN treated group, one rat
did not show any infarction by TTC staining and was
excluded. Therefore, three animals in ET-1 group and
four animals in ET-1 plus pGSN group were examined
for behavioral deficits and brain damage.
Cylinder test
As shown in Figure 2, ET-1 induced MCAO resulted in
profound impairment of contralateral forepaw function
three days following injection. ET-1-treated animals
showed significant reduction of symmetrical forepaw use
during wall exploration (from approximately 80% to
20%), while artificial cerebrospinal fluid (aCSF) injection
had no effect. In the pGSN treatment group, the percen-
tage of symmetrical forepaw use was significantly higher
than the control group (20% vs. 70%, p-value < 0.01).
The number of attempts to explore the wall was also
lower than before surgery (data is not shown). These
results indicate that pGSN treatment significantly pre-
vented MCAO-induced damage to the motor system.
Vibrissae test
To test the effect of pGSN on sensorimotor system, we
also performed vibrissae testing. As expected, vibrissae-
stimulated placing of the ipsilateral forepaw was not
affected 3 days after experimental ischemic stroke (Fig-
ure 3A). Contralateral forepaw placing was significantly
slowed (from 1 s to 18 s) in the control (ET-1 alone)
group (Figure 3B). Intriguingly, pGSN treatment signifi-
cantly reduced the time of contralateral forepaw placing
compared to control group (18 s vs. 9 s, p-value < 0.01).
These results indicated that pGSN treatment signifi-
cantly prevented the loss of sensorimotor function
induced by MCAO.
Treatment of pGSN reduced MCAO induced brain
damage
In the control rats, ET-1 produced large and reproduci-
ble unilateral infarcts that involved the rostro-central
dorsolateral cortex and basal ganglia, corresponding to
the full extent of the MCA territory. The infarction
volume in the pGSN-treatment group was reduced by
49% compared to the control group (Figure 4). Sparing
was observed in both cortical and subcortical structures.
Discussion
The current study reports the first time use of pGSN as
a protein drug to reduce injury after transient local
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Page 4 of 9Figure 1 Perfusion measurements. (A) Color photographs of an animal brain recorded at different time points (pre-injection, 10-20 min, 30-35
min, and 60-65 min from ET-1 injection time) by a digital camera of laser Doppler system, corresponding closely with the blood flow image.
Look-up table shows arbitrarily assigned perfusion unit (PU) from the lower limit 0 to upper limit 1, 000 and above. The scalps demonstrate the
holes and injection sites. (B) Percentage perfusion reduction as a function of time calculated using formula 1. All rats were injected with ET-1
(240 pmol in 3 μL PBS) proximal to the left middle cerebral artery. About 5-10 min after ET-1 injection, pGSN (35.71 pmol in 3 μL saline) was
intracranially injected (i.c) at the same site in a group and no injection in the other group. The dotted line represents the average levels in pGSN
treated group (N = 3). The solid line represent levels in control group (N = 3). The differences at all-time points were not statically significant.
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improve sensorimotor recovery in conjunction with sub-
stantial reduction in infarct volume present three days
after stroke.
Transient middle cerebral artery occlusion (tMCAO)
induced by ET-1, a potent vasoconstriction peptide,
decreased relative cerebral blood flow in brain tissue
served by the MCA by 50% in all groups. In previous
studies, injection of ET-1 adjacent to MCA has been
shown to reduce blood flow 30-75% in the region sup-
plied by the artery including cortex and basal ganglia,
and to produce subsequent ischemic neuropathology in
these regions of the brain [24,25,29].
Our results demonstrate that after 10-20 min follow-
ing ET-1 intracranial injection, the ipsilateral cerebral
relative blood flow decreased approximately 50% in all
groups of animals (Figure 1), indicating that all animals
initially have comparable ischemic strokes and that
pGSN did not reduce the magnitude of the original
ischemic event, but limited the subsequent degeneration
and associated loss of function. This suggests that pGSN
does not interfere with ET-1 action on its receptors, and
corresponds to studies in which GSN knockout mice
had larger infarct volume at 22 h even though reduc-
tions in CBF during MCAO were not altered [23].
Although this study shows that pGSN in or near an
infarct can reduce neuropathology and functional loss
due to ischemic stroke, the mechanism by which pGSN
mediates protection are not yet clear. One likely
mechanism involves actin depolymerization. Upon tissue
Figure 2 Cylinder test. Rats were placed in a transparent cylinder
for 3 min. Animal forepaws used during exploration were scored.
Each bar represents the average fraction of using both forepaws in
the indicated group. ET-1 group, N = 3, ET-1 + pGSN, N = 4, *: p-
value < 0.05; **, p-value < 0.01, ***, p-value < 0.001.
Figure 3 Vibrissae test. (A) Time in seconds to ipsilateral forepaw
placement on the countertop. (B) Time in seconds to contralateral
forepaw placement on the countertop, ET-1 group, N = 3, ET-1 +
pGSN, N = 4, **: p-value < 0.01.
Figure 4 Infarction area labeled for mitochondrial activity
(triphenyltetrazolium chloride, TTC). ET-1-alone group N = 3,
pGSN treatment group, N = 4. *, p-value < 0.05. Four TTC-staining
slices from two animals, one for each group, at the area received
most of blood from MCA. Off-white color areas show death tissues
while red areas indicate vital tissues.
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cantly reduced), large amounts of actin can be released
from damaged cells into the extracellular space. Since
the ionic conditions in the extracellular fluid favor actin
polymerization, high amounts of F-actin could be
r e l e a s e dt op o t e n t i a l l yi n c r e a s et h ev i s c o s i t yo fb l o o d
and perturb blood flow through the microvasculature.
The actin severing protein gelsolin has a secreted
plasma isoform (called plasma gelsolin), which is consti-
tutively active in the high extracellular calcium concen-
trations of plasma. Plasma gelsolin severs extracellular
F-actin to short filaments, and by capping barbed ends,
prevents polymerization and favors monomer release.
Therefore, pGSN acts as “debris cleaner” limiting
inflammation and possibly decrease blood clogging [22].
Another possible mechanism is through anti-apoptotic
activity of pGNS. In Jurkat cells, overexpression of gel-
solin inhibites cytokine induced apoptosis [30]. It has
been reported that gelsolin can form complex with
phosphatidylinositol 4, 5-bisphosphate and inhibit
capase-3 and -9 activities [31]. In addition, pGSN may
also play an important role in regulating inflammation.
Future studies will focus on the mechanisms of pGSN
protection.
Histone deacetylase inhibitor-mediated neuroprotec-
tion against MCAO has been associated with GSN upre-
gulation and reductions in filamentous actin, neither of
which was shown to occur in GSN-knockout mice in
which the treatment was ineffective [32]. Also, GSN can
modulate the actin cytoskeleton regulation of numerous
ion channels responsible for elevated cytotoxic intracel-
lular calcium and glutamate excitotoxicity [33-35].
Gelsolin is regulated by phosphatidylinositol 4, 5-
bisphosphate (PIP2), and contains a lipid signaling bind-
ing domain. This domain has been shown to bind to a
number of bioactive lipids including lysophosphatidic
acid (LPA), lipoteichoic acid (LTA), and lipopolysac-
charide (LPS) [36-39]. LPA levels have been shown to
be increased in patients suffering ischemic stroke [40].
LPA signaling has also been shown to regulate a num-
ber of pro-inflammatory genes [41]. Increasing gelsolin
levels during stroke may serve to modulate the inflam-
matory response thereby offering protection against the
inflammation related neurodegeneration following
stroke.
Further emphasis of the potential importance of GSN
in stroke comes from recent reports that circulating
pGSN levels are reduced in ischemic stroke suffers and
is highly predictive for first-year mortality from ischemic
stroke [37]. Matrix metalloproteinases (MMPs), zinc-
containing endopeptidases that participate in both nor-
mal and pathological processes, are upregulated during
inflammatory conditions [42], including stroke [43].
pGSN is cleaved in vitro by MMP-3, MMP-2, MMP-1,
MMP-14 and MMP-9 [44] which may be the cause of
the severe depletion of pGSN observed in patients who
suffer ischemic stroke. Replacing lost pGSN may inter-
rupt pro-inflammatory cascade and result in decreased
brain damage.
Conclusion
T h ec u r r e n ts t u d yo f f e r sap r o o fo fp r i n c i p l et h a t
delivery of pGSN following ischemic stroke results in
neuroprotection and can reduce both sensory and
motor deficits that arise following stroke. Future
research aimed at characterizing improved delivery,
dose response, temporal, safety, pharmacokinetic
issues, and physiological mechanisms for further pre-
clinical development of this promising strategy are
called for.
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